Recurrence of VTE Associated with COVID-19 is Unlikely After Stopping Anticoagulation
June 1, 2023
Dr. Sullivan Clinical question: How long should anticoagulation be continued after COVID-19-associated venous thromboembolism (VTE)? Background: COVID-19 infection is associated with an...
FAST Program Implementation Guide Success
February 1, 2023
Jefferson Antithrombotic Therapy Team. Front row L to R: Photi Galanis, MD, Julia Westfield, Heather Yenser, CRNP. Back row L to R: Lynda Thomson, PharmD, Dina Orapallo, CRNP, Geno Merli, MD, Tony...
Consider post-discharge VTE prophylaxis for COVID-19 patients
April 1, 2022
Dr. Indovina Clinical question: Should extended post-discharge venous thromboembolism (VTE) prophylaxis be prescribed for patients with COVID-19? Background: While VTE prophylaxis during...
Higher-than-expected recurrent VTE found in patients with isolated SSPE
April 1, 2022
Dr. Munoa Clinical question: What is the recurrence rate of venous thromboembolism (VTE) in patients with isolated subsegmental pulmonary embolisms (SSPE) managed without...
Direct oral anticoagulants may be safe in cancer-related venous thromboembolisms, but use caution with gastrointestinal malignancies
February 3, 2022
Clinical question: Are direct oral anticoagulants (DOACs) a suitable alternative to low molecular weight heparin (LMWH) for treatment of venous thromboembolism (VTE) in patients with underlying...
D-dimer thresholds rule out PE in meta-analysis
December 14, 2021
Data from a large review support use of D-dimer levels to diagnose PE without imaging.
Apixaban outmatches rivaroxaban for VTE in study
December 6, 2021
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
D-dimer unreliable for ruling out pulmonary embolism in COVID-19
October 14, 2021
“These results suggest that use of D-dimer levels to exclude PE among patients hospitalized with COVID-19 may be inappropriate and have limited clinical utility.”
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
October 11, 2021
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
Refined heart rate cutoffs may improve prognostic value of acute PE scoring systems
September 21, 2021
In an observational registry-based study, dropping the 110-bpm heart rate threshold improved sensitivity for low-risk PE, while increasing it improved specificity for intermediate-high–risk PE.